AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
The main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes.
learn about our work
Neurodegenerative Disease Areas
This two-day event, which immediately precedes Rare Disease Day on February 28, 2018, will be held at the Icagen Oro Valley location (North of Tucson). The Symposium will feature presentations from a mix of academic and industry speakers from the pharmaceutical and biotechnology communities as well as key opinion leaders from foundations committed to the identification, treatment, and cure of rare diseases.
The award recognizes Dr. Ichida's "pioneering work to convert patients’ skin cells into disease-affected neural cells, enabling them to screen thousands of drug-like compounds in search of potential therapeutics that could slow or stop ALS."